Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia

Journal of Clinical Lipidology

Volumn 5, Issue 6, 2011, Pages 483-492

  Maki, Kevin C ^a   Bays, Harold E ^b   Dicklin, Mary R ^a   Johnson, Susan L ^c   Shabbout, Mayadah ^c  

^a Provident Clinical Research   (United States)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Apolipoprotein CIII; Lipoprotein particles; Lipoprotein associated phospholipase A2; Omega 3 fatty acids; Statins; Triglycerides

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN C3; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID ESTER; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED DYSLIPIDEMIA; PARTICLE SIZE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; AGED; APOLIPOPROTEIN C-III; CHOLESTEROL, LDL; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EICOSAPENTAENOIC ACID; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81855170281     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.09.001     Document Type: Article

References (60)

1. H.N. Ginsberg Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy Am J Cardiol 87 2001 1174 1180 (Pubitemid 32453238)
2. J. Liu, C.T. Sempos, R.P. Donahue, J. Dorn, M. Trevisan, and S.M. Grundy Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease Am J Cardiol 98 2006 1363 1368 (Pubitemid 44666646)
3. N. Sarwar, J. Danesh, and G. Eiriksdottir Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458 (Pubitemid 46184196)
4. J.J. Kastelein, W.A. van der Steeg, I. Holme TNT Study Group; IDEAL Study Group Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
5. E.S. Ford, C. Li, G. Zhao, W.S. Pearson, and A.H. Mokdad Hypertriglyceridemia and its pharmacologic treatment among US adults Arch Intern Med 169 2009 572 578
6. W.S. Harris N-3 fatty acids and serum lipoproteins: human studies Am J Clin Nutr 65 5 suppl 1997 1645S 1654S (Pubitemid 27187958)
7. K.C. Maki, B.C. Lubin, M.S. Reeves, M.R. Dicklin, and W.S. Harris Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg; effects in mixed dyslipidemia J Clin Lipidol 3 2009 33 38
8. A. Nordøy, K.H. Bønaa, H. Nilsen, R.K. Berge, J.B. Hansen, and O.C. Ingebretsen Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia J Intern Med 243 1998 163 170 (Pubitemid 28156665)
9. P.N. Durrington, D. Bhatnagar, and M.I. Mackness An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia Heart 85 2001 544 548 (Pubitemid 32973499)
10. D.C. Chan, G.F. Watts, P.H. Barrett, L.J. Beilin, T.G. Redgrave, and T.A. Mori Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia Diabetes 51 2002 2377 2386 (Pubitemid 34827385)
11. K.C. Maki, J.M. McKenney, M.S. Reeves, B.C. Lubin, and M.R. Dicklin Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia [Erratum appears in Am J Cardiol. 2008;102:1425.] Am J Cardiol 102 2008 429 433
12. M.H. Davidson, K.C. Maki, H. Bays, R. Carter, and C.M. Ballantyne Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia J Clin Lipidol 3 2009 332 340
13. H.E. Bays, J. McKenney, K.C. Maki, R.T. Doyle, R.N. Carter, and E. Stein Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin Mayo Clin Proc 85 2010 122 128
14. M.A. Austin, M.C. King, K.M. Vranizan, and R.M. Krauss Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk Circulation 82 1990 495 506 (Pubitemid 20257828)
15. M.J. Chapman, M. Guérin, and E. Bruckert Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches Eur Heart J Supp A 1998 A24 A30 (Pubitemid 28112474)
16. T. Björnheded, A. Babyi, G. Bondjers, and O. Wiklund Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system Atherosclerosis 123 1996 43 56 (Pubitemid 26175068)
17. H. Bays, S. Conard, and L.A. Leiter Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Lipids Health Dis 9 2010 136
18. C.U. Choi, H.S. Seo, and E.M. Lee Statins do not decrease small, dense low-density lipoprotein Tex Heart Inst J 37 2010 421 428
19. J.D. Otvos, D. Collins, and D.S. Freedman Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorable changes by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention trial Circulation 113 2006 1556 1563 (Pubitemid 43739414)
20. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, and D.C. Goff Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
21. W.C. Cromwell, J.D. Otvos, and M.J. Keyes LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management J Clin Lipidol 1 2007 583 592 (Pubitemid 350215511)
22. K. El Harchaoui, W.A. van der Steeg, and E.S. Stroes Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study J Am Coll Cardiol 49 2007 547 553 (Pubitemid 46177441)
23. J. Hsia, J.D. Otvos, J.E. Rossouw Women's Health Initiation Research Group Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials Arterioscler Thromb Vasc Biol 28 2008 1666 1671
24. S. Mora, J.D. Otvos, N. Rifai, R.S. Rosenson, J.E. Buring, and P.M. Ridker Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 2009 931 939
25. H.N. Ginsberg, N.A. Le, and I.J. Goldberg Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo J Clin Invest 78 1986 1287 1295 (Pubitemid 17181567)
26. H.N. Ginsberg, and W.V. Brown Apolipoprotein CIII. 42 years old and even more interesting Arterioscler Thromb Vasc Biol 31 2011 471 473
27. F.M. Sacks, P. Alaupovic, and L.A. Loye VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial Circulation 102 2000 1886 1892
28. Y. Gerber, U. Goldbourt, S. Segev, and D. Harats Indices related to Apo CII and CIII serum concentrations and coronary heart disease: a case control study Prev Med 37 2003 18 22 (Pubitemid 36687861)
29. S.J. Lee, and F.M. Sacks Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus Am J Cardiol 92 2003 121 124 (Pubitemid 36835957)
30. A. Kawakami, M. Osaka, and M. Tani Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction Circulation 118 2008 731 742
31. I. Gazi, E.S. Lourida, T. Filippatos, V. Tsimihodimos, M. Elisaf, and A.D. Tselepis Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma Clin Chem 51 2005 2264 2273 (Pubitemid 41692569)
32. J.W. Gaubatz, B.K. Gillard, and J.B. Massey Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2) J Lipid Res 48 2007 348 357 (Pubitemid 46220601)
33. C.C. Tellis, and A.D. Tselepis The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma Biochim Biophys Acta 1791 2009 327 338
34. A.D. Tselepis, and M.J. Chapman Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase Atheroscler Suppl 3 2002 57 68 (Pubitemid 38234487)
35. R.J. Chauffe, R.L. Wilensky, and E.R. Mohler 3rd Recent developments with lipoprotein-associated phospholipase A2 inhibitors Curr Atheroscler Rep 12 2010 43 47
36. W. Koenig, N. Khuseyinova, H. Löwel, G. Trischler, and C. Meisinger Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany Circulation 110 2004 1903 1908 (Pubitemid 39331899)
37. K. Sudhir Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction Vasc Health Risk Manag 2 2006 153 156 (Pubitemid 43853429)
38. J.L. Anderson Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention Am J Cardiol 101 2008 23F 33F
39. V.G. Saougos, A.P. Tambaki, and M. Kalogirou Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2 Arterioscler Thromb Vasc Biol 27 2007 2236 2243 (Pubitemid 350287255)
40. L.T. Braun, and M.H. Davidson Lp-PLA2: A new target for statin therapy Curr Atheroscler Rep 12 2010 29 33
41. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report Circulation 106 2002 3143 3421
42. R.C. Block, W.S. Harris, K.J. Reid, S.A. Sands, and J.A. Spertus EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls Atherosclerosis 197 2008 821 828 (Pubitemid 351417881)
43. M.J. Caslake, C.J. Packard, K.E. Suckling, S.D. Holmes, P. Chamberlain, and C.H. Macphee Lipoprotein-associated phospholipase A(2), platelet activating factor acetylhydrolase: a potential new risk for coronary artery disease Atherosclerosis 150 2000 413 419 (Pubitemid 30336554)
44. A.C. Rustan, and C.A. Drevon Eicosapentaenoic acid inhibits hepatic production of very low density lipoprotein J Intern Med Suppl 731 1989 31 38 (Pubitemid 19191744)
45. H.E. Bays, A.P. Tighe, R. Sadovsky, and M.H. Davidson Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications Exp Rev Cardiovasc Ther 6 2008 391 409
46. W.S. Harris, M. Miller, A.P. Tighe, M.H. Davidson, and E.J. Schaefer Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives Atherosclerosis 197 2008 12 24
47. P.C. Dagnelie, T. Rietveld, G.R. Swart, T. Stijnen, and J.W. van den Berg Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies and triacylglycerol in humans Lipids 29 1994 41 45 (Pubitemid 24034111)
48. K. Schoonjans, B. Staels, and J. Auwerx The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation Biochim Biophys Acta 1302 1996 93 109 (Pubitemid 26247079)
49. M.W. Huff, and D.E. Telford Dietary fish oil increases conversion of very low density lipoprotein apoprotein B to low density lipoprotein Arteriosclerosis 9 1989 58 66 (Pubitemid 19046091)
50. L. Calabresi, D. Donati, F. Pazzucconi, C.R. Sirtori, and G. Franceschini Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses Atherosclerosis 148 2000 387 396 (Pubitemid 30064470)
51. D.C. Chan, G.F. Watts, T.A. Mori, P.H. Barrett, T.G. Redgrave, and L.J. Beilin Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity Am J Clin Nutr 77 2003 300 307 (Pubitemid 36133369)
52. H.C. Bucher, P. Hengstler, C. Schindler, and G. Meier N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials Am J Med 112 2002 298 304 (Pubitemid 34219443)
53. M.H. Davidson, E.A. Stein, H.E. Bays, K.C. Maki, R.T. Doyle, R.A. Shalwitz, C.M. Ballantyne, H.N. Ginsberg COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 29 2007 1354 1367 (Pubitemid 47348116)
54. K. Aalto-Setälä, E.A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H.N. Ginsberg, and J.L. Breslow Mechanism of hypertriglyceridemia in human apolipoprotein (Apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased Apo CIII and reduced Apo E on the particles J Clin Invest 90 1992 1889 1900
55. K.C. Maki, M.R. Dicklin, M.H. Davidson, R.T. Doyle, C.M. Ballantyne COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy Am J Cardiol 105 2010 1409 1412
56. C.J. Packard Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein Biochem Soc Trans 31 Pt 5 2003 1066 1069 (Pubitemid 37305047)
57. M.H. Davidson, H.E. Bays, E. Stein, K.C. Maki, R.A. Shalwitz, R. Doyle TRIMS Investigators Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects Clin Cardiol 29 2006 268 273 (Pubitemid 43865706)
58. G.L. Vega, P.T. Ma, N.B. Cater, N. Filipchuk, S. Meguro, A.B. Garcia-Garcia, and S.M. Grundy Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome Am J Cardiol 91 2003 956 960 (Pubitemid 36398528)
59. W.S. Harris, S.A. Sands, and S.L. Windsor Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation Circulation 110 2004 1645 1649 (Pubitemid 39297988)
60. W.S. Harris, J.V. Pottala, S.A. Sands, and P.G. Jones Comparisons of the effects of fish and fish-oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids Am J Clin Nutr 86 2007 1621 1625 (Pubitemid 350232175)